Expression of IFITM1 in chronic myeloid leukemia patients.
We investigated the peripheral blood gene expression profile of interferon induced transmembrane protein 1 (IFITM1) in sixty chronic myeloid leukemia (CML) patients classified according to new prognostic score (NPS). IFITM1 is a component of a multimeric complex involved in the trunsduction of antiproliferative and cell adhesion signals. Expression level of IFITM1 was found significantly different between the high- and low-risk groups (P = 9.7976 x 10(-11)) by real-time reverse transcription polymerase chain reaction (RT-PCR). Higher IFITM1 expression correlated with improved survival (P = 0.01). These results indicate that IFITM1 expression profiling could be used for molecular classification of CML, which may also predict survival.
Akyerli
Cemaliye Boylu
CB
Department of Molecular Biology and Genetics, Bilkent University, Bilkent, 06800 Ankara, Turkey.
Beksac
Meral
M
Holko
Michelle
M
Frevel
Mathias
M
Dalva
Klara
K
Ozbek
Uğur
U
Soydan
Ender
E
Ozcan
Muhit
M
Ozet
Gülsüm
G
Ilhan
Osman
O
Gürman
Günhan
G
Akan
Hamdi
H
Williams
Bryan R G
BR
Ozçelik
Tayfun
T
D000328:Adult; D000368:Aged; D000943:Antigens, Differentiation; D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000145:classification / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
D000943:Antigens, Differentiation; D014408:Biomarkers, Tumor; D008565:Membrane Proteins; C062010:leu-13 antigen